Biosimilars are highly similar to, but have no clinically meaningful differences when compared with the original biological drug. Biosimilar antibodies are produced by recombinant DNA technology and expressed in CHO cells. These drugs have been broadly employed in the treatment of various cancers and autoimmune diseases, and most recently as therapy against the SARS-CoV-2 coronavirus. Check out BioVision’s selection of biosimilar monoclonal antibodies to study and improve targeted therapy strategies.
